Trodelvy 180 (Sacituzumab govitecan-hziy Vials) 180mg

Trodelvy 180mg (sacituzumab govitecan-hziy) is an FDA-approved therapy for metastatic breast cancer in adults. This injectable formulation targets HER2-negative tumors. Discover how Trodelvy 180mg works and its role in cancer treatment options.

Strength

180mg

Manufacturer / TM Owner

Immunomedics Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Trodelvy 180mg is used to treat metastatic triple-negative breast cancer in adults who have received at least two prior therapies. It is designed for patients whose cancer has spread to other parts of the body. This medication is also indicated for certain types of metastatic breast cancer that are hormone receptor-negative and HER2-negative. Patients should consult their healthcare provider to determine if Trodelvy 180mg is appropriate for their condition.

Side Effects

Trodelvy 180mg works by targeting cancer cells and delivering chemotherapy directly to them, which may help reduce damage to healthy cells. Common effects include fatigue, nausea, and hair loss, though these vary by individual. Some patients may experience changes in appetite or digestive discomfort during treatment.

Precautions & Warnings

Trodelvy 180mg should only be handled and administered by healthcare professionals in a clinical setting. Patients should inform their doctor about all medications and conditions before starting treatment. Regular monitoring is required to manage potential side effects and ensure safety during therapy.

Avoid Interactions

Trodelvy 180mg may interact with other medications, including strong CYP3A4 inhibitors or inducers, which can affect its effectiveness. Patients should avoid live vaccines while undergoing treatment. Alcohol and certain supplements may also interact, so a healthcare provider should review all concurrent therapies.

Frequently Asked Questions

Trodelvy 180mg is used to treat metastatic triple-negative breast cancer in adults who have received prior therapies.

Trodelvy 180mg is given as an intravenous infusion by a healthcare professional in a clinical setting.

Common side effects may include fatigue, nausea, and hair loss, though individual experiences vary.

Patients should inform their doctor about all medications to avoid potential interactions during treatment.

Trodelvy 180mg is an antibody-drug conjugate that delivers chemotherapy directly to cancer cells.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.